Becton Dickinson/Abbott
This article was originally published in The Gray Sheet
Executive Summary
Immunological platelet analysis assay using BD's CD61 fluorescence-labeled monocolonal antibody and Abbott's Cell-Dyn 4000 hematology system will be the first product from the firms' new alliance aimed at developing novel fully automated immuno-hematology applications. The deal calls for combining Abbott's automated hematology systems with BD's flow cytometry, reagent technology and blood collection systems. Other applications in the pipeline include CD4 and CD8 count capability for the Cell-Dyn 4000
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.